Skip to content
DraconiticResearch
Search Sources API
220,618 studies31 sourcesUpdated 1 min ago
Peer-reviewedCC BY-NC 4.0Korean Journal of Radiology

Imaging of Isocitrate Dehydrogenase-Mutant Gliomas in the Era of Isocitrate Dehydrogenase Inhibitors: What Radiologists Need to Know

  • Yae Won Park1
  • Arthur Wagner2
  • Philipp Karschnia2
  • Philipp Vollmuth3,4,5
  • Felix Sahm6,7
  • Sung Soo Ahn8
  • Ho Sung Kim1
  • Ji Eun Park9
9 affiliations
  1. 1Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea .
  2. 2Department of Neurosurgery, Technical University of Munich, Munich, Germany .
  3. 3Department of Neuroradiology, University Hospital Bonn, Bonn, Germany .
  4. 4Division for Computational Radiology & Clinical AI (CCIBonn.ai), University Hospital Bonn, Bonn, Germany .
  5. 5Division for Medical Image Computing (MIC), German Cancer Research Center (DKFZ), Heidelberg, Germany .
  6. 6Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany .
  7. 7Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany .
  8. 8Department of Radiology and Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonsei University College of Medicine, Seoul, Republic of Korea .
  9. 9Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA .
Read full textDOICite

Abstract

Isocitrate dehydrogenase (IDH)-mutant gliomas, including IDH-mutant astrocytomas and IDH-mutant and 1p/19q-codeleted oligodendrogliomas, exhibit biologically distinct behaviors from IDH-wildtype glioblastomas, showing better survival outcomes and requiring different treatment strategies. The recent FDA approval of vorasidenib, an IDH mutation inhibitor, has introduced a paradigm shift in the treatment of IDH-mutant gliomas and has focused attention to the role of imaging information in the routine clinical management of these tumors. In this review, we provide an overview of the clinical fundamentals of IDH-mutant gliomas and highlight the preoperative and postoperative imaging features of these lesions, which are important for radiologists to recognize and communicate with clinicians.

Related

  1. Enhancing 1p/19q Classification in Brain Gliomas Using Isocitrate Dehydrogenase Status: A Deep Learning Study
    Jason E. Bowerman, Ashwath S. Kapilavai, Benjamin C. Wagner +13
    AJNR: American Journal of NeuroradiologyPeer-reviewedLicence not statedFull textGeneral medicinePMC
  2. From Cellular Origin to Clinical Recurrence: Rethinking Tumor Boundaries in Isocitrate Dehydrogenase-Mutant Gliomas
    Jung Won Park
    Brain Tumor Research and TreatmentPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  3. Discovery of Covalent Wild-Type Isocitrate Dehydrogenase 1 (IDH1) Inhibitors Targeting Cys269
    C. P. Brown, E. O. Harmer, A. Azam +5
    bioRxivPreprintCC BYFull textOncologybioRxiv
  4. Targeting Isocitrate Dehydrogenase-Mutant Glioma with Vorasidenib : A New Era in Precision Neuro-Oncology
    Kyung-Min Kim, Yukyeng Byeon, Chaejin Lee +9
    Journal of Korean Neurosurgical SocietyPeer-reviewedCC BY-NC 4.0Full text1 citedOncologyPMC
  5. Mutant Isocitrate Dehydrogenase 1 Alters Extracellular Vesicle Secretion and Cargo Composition in Cellular Models
    G. Chao, A. V. Schwartz, R. Hobbs +7
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{park2026imaging,
  title = {{Imaging of Isocitrate Dehydrogenase-Mutant Gliomas in the Era of Isocitrate Dehydrogenase Inhibitors: What Radiologists Need to Know}},
  author = {Yae Won Park and Arthur Wagner and Philipp Karschnia and Philipp Vollmuth and Felix Sahm and Sung Soo Ahn and Ho Sung Kim and Ji Eun Park},
  journal = {Korean Journal of Radiology},
  year = {2026},
  month = oct,
  doi = {10.3348/kjr.2026.1078},
  url = {https://doi.org/10.3348/kjr.2026.1078},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Imaging of Isocitrate Dehydrogenase-Mutant Gliomas in the Era of Isocitrate Dehydrogenase Inhibitors: What Radiologists Need to Know
AU  - Yae Won Park
AU  - Arthur Wagner
AU  - Philipp Karschnia
AU  - Philipp Vollmuth
AU  - Felix Sahm
AU  - Sung Soo Ahn
AU  - Ho Sung Kim
AU  - Ji Eun Park
PY  - 2026
DA  - 2026/10/26
JO  - Korean Journal of Radiology
DO  - 10.3348/kjr.2026.1078
UR  - https://doi.org/10.3348/kjr.2026.1078
AB  - Isocitrate dehydrogenase (IDH)-mutant gliomas, including IDH-mutant astrocytomas and IDH-mutant and 1p/19q-codeleted oligodendrogliomas, exhibit biologically distinct behaviors from IDH-wildtype glioblastomas, showing better survival outcomes and requiring different treatment strategies. The recent FDA approval of vorasidenib, an IDH mutation inhibitor, has introduced a paradigm shift in the treatment of IDH-mutant gliomas and has focused attention to the role of imaging information in the routine clinical management of these tumors. In this review, we provide an overview of the clinical fundamentals of IDH-mutant gliomas and highlight the preoperative and postoperative imaging features of these lesions, which are important for radiologists to recognize and communicate with clinicians.
SN  - 1229-6929
SN  - 2005-8330
ER  -